Compare VINP & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VINP | PACB |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.8M | 521.8M |
| IPO Year | 2020 | 2010 |
| Metric | VINP | PACB |
|---|---|---|
| Price | $9.79 | $1.51 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $14.00 | $1.67 |
| AVG Volume (30 Days) | 62.3K | ★ 5.8M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | $18.07 | $11.32 |
| Revenue Next Year | $12.74 | $12.14 |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $9.20 | $1.09 |
| 52 Week High | $13.61 | $2.73 |
| Indicator | VINP | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 50.33 |
| Support Level | $9.61 | $1.46 |
| Resistance Level | $10.24 | $1.78 |
| Average True Range (ATR) | 0.37 | 0.13 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 13.14 | 40.74 |
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.